GENE ONLINE|News &
A Boom in High-Value M&A and Licensing Deals in the Exosome Field
During the pandemic, the growth of most biopharma businesses had slowed down, except for COVID-19 vaccines and therapies. Yet, exosome-related deals have thrived even under such difficult circumstances, shedding light on the tremendous potential of startups and ground-breaking technologies. Who are the buyers? And who are the rising stars?
Exosome as IVD: M&A
The most significant med-tech application of exosomes is the ExoDx Prostate Test (EPI), developed by Exosome Diagnostics Inc. (Exosome Dx), now part of Bio-Techne Corp. (NASDAQ: TECH).
EPI, the first exosome-based liquid biopsy test to receive FDA breakthrough
Exosome as IVD: M&A
The most significant med-tech application of exosomes is the ExoDx Prostate Test (EPI), developed by Exosome Diagnostics Inc. (Exosome Dx), now part of Bio-Techne Corp. (NASDAQ: TECH).
EPI, the first exosome-based liquid biopsy test to receive FDA breakthrough
GO Prime with only $1.49 now
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
